S&P 500   3,323.91 (+0.07%)
DOW   29,165.26 (-0.07%)
QQQ   224.41 (+0.24%)
AAPL   318.88 (+0.37%)
FB   220.50 (-0.37%)
MSFT   166.17 (+0.28%)
GOOGL   1,486.82 (+0.18%)
AMZN   1,884.90 (-0.14%)
CGC   24.31 (+0.79%)
NVDA   253.07 (+1.21%)
BABA   219.34 (-1.36%)
MU   59.22 (+0.08%)
GE   11.83 (+4.05%)
TSLA   565.82 (-0.66%)
AMD   51.50 (+0.14%)
T   38.69 (-0.90%)
ACB   2.04 (+0.00%)
F   9.11 (-0.55%)
NFLX   342.19 (+4.97%)
BAC   34.16 (-0.58%)
DIS   142.37 (-1.14%)
GILD   63.82 (+0.60%)
S&P 500   3,323.91 (+0.07%)
DOW   29,165.26 (-0.07%)
QQQ   224.41 (+0.24%)
AAPL   318.88 (+0.37%)
FB   220.50 (-0.37%)
MSFT   166.17 (+0.28%)
GOOGL   1,486.82 (+0.18%)
AMZN   1,884.90 (-0.14%)
CGC   24.31 (+0.79%)
NVDA   253.07 (+1.21%)
BABA   219.34 (-1.36%)
MU   59.22 (+0.08%)
GE   11.83 (+4.05%)
TSLA   565.82 (-0.66%)
AMD   51.50 (+0.14%)
T   38.69 (-0.90%)
ACB   2.04 (+0.00%)
F   9.11 (-0.55%)
NFLX   342.19 (+4.97%)
BAC   34.16 (-0.58%)
DIS   142.37 (-1.14%)
GILD   63.82 (+0.60%)
S&P 500   3,323.91 (+0.07%)
DOW   29,165.26 (-0.07%)
QQQ   224.41 (+0.24%)
AAPL   318.88 (+0.37%)
FB   220.50 (-0.37%)
MSFT   166.17 (+0.28%)
GOOGL   1,486.82 (+0.18%)
AMZN   1,884.90 (-0.14%)
CGC   24.31 (+0.79%)
NVDA   253.07 (+1.21%)
BABA   219.34 (-1.36%)
MU   59.22 (+0.08%)
GE   11.83 (+4.05%)
TSLA   565.82 (-0.66%)
AMD   51.50 (+0.14%)
T   38.69 (-0.90%)
ACB   2.04 (+0.00%)
F   9.11 (-0.55%)
NFLX   342.19 (+4.97%)
BAC   34.16 (-0.58%)
DIS   142.37 (-1.14%)
GILD   63.82 (+0.60%)
S&P 500   3,323.91 (+0.07%)
DOW   29,165.26 (-0.07%)
QQQ   224.41 (+0.24%)
AAPL   318.88 (+0.37%)
FB   220.50 (-0.37%)
MSFT   166.17 (+0.28%)
GOOGL   1,486.82 (+0.18%)
AMZN   1,884.90 (-0.14%)
CGC   24.31 (+0.79%)
NVDA   253.07 (+1.21%)
BABA   219.34 (-1.36%)
MU   59.22 (+0.08%)
GE   11.83 (+4.05%)
TSLA   565.82 (-0.66%)
AMD   51.50 (+0.14%)
T   38.69 (-0.90%)
ACB   2.04 (+0.00%)
F   9.11 (-0.55%)
NFLX   342.19 (+4.97%)
BAC   34.16 (-0.58%)
DIS   142.37 (-1.14%)
GILD   63.82 (+0.60%)
Log in

NASDAQ:XBIT - XBiotech Stock Price, Forecast & News

$22.82
+0.25 (+1.11 %)
(As of 01/23/2020 02:32 PM ET)
Today's Range
$22.52
Now: $22.83
$22.92
50-Day Range
$10.99
MA: $19.29
$24.90
52-Week Range
$5.44
Now: $22.83
$26.40
Volume637,633 shs
Average Volume863,306 shs
Market Capitalization$937.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.16 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees56
Market Cap$937.88 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.15). View XBiotech's Earnings History.

When is XBiotech's next earnings date?

XBiotech is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for XBiotech.

What price target have analysts set for XBIT?

1 brokers have issued twelve-month target prices for XBiotech's stock. Their forecasts range from $28.00 to $28.00. On average, they expect XBiotech's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 22.9% from the stock's current price. View Analyst Price Targets for XBiotech.

What is the consensus analysts' recommendation for XBiotech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.

Has XBiotech been receiving favorable news coverage?

News coverage about XBIT stock has trended somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. XBiotech earned a news impact score of 1.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for XBiotech.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,590,000 shares, an increase of 10.8% from the December 15th total of 3,240,000 shares. Based on an average daily trading volume, of 311,500 shares, the days-to-cover ratio is presently 11.5 days. Currently, 20.2% of the company's shares are sold short. View XBiotech's Current Options Chain.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Who are XBiotech's major shareholders?

XBiotech's stock is owned by many different of institutional and retail investors. Top institutional investors include Silverleafe Capital Partners LLC (0.06%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.

Which institutional investors are buying XBiotech stock?

XBIT stock was bought by a variety of institutional investors in the last quarter, including Silverleafe Capital Partners LLC. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $22.79.

How big of a company is XBiotech?

XBiotech has a market capitalization of $936.44 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.

What is XBiotech's official website?

The official website for XBiotech is http://www.xbiotech.com/.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]


MarketBeat Community Rating for XBiotech (NASDAQ XBIT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel